Ibalizumab in Multidrug-Resistant HIV - Accepting Uncertainty

N Engl J Med. 2018 Aug 16;379(7):605-607. doi: 10.1056/NEJMp1808729.

Authors

Virginia Sheikh¹, Jeffrey S Murray¹, Adam Sherwat¹

Affiliation

¹ From the Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.

PMID: 30110580
DOI: 10.1056/NEJMp1808729

No abstract available

MeSH terms

Anti-HIV Agents / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Disease Progression
Drug Resistance, Multiple, Viral*
HIV Fusion Inhibitors / therapeutic use*
HIV Infections / drug therapy*
Humans
Research Design
Uncertainty

Substances

Anti-HIV Agents
Antibodies, Monoclonal
HIV Fusion Inhibitors
ibalizumab